Teams Advisory Board


Gowthami Arepally, M.D

Gowthami Arepally, M.D

Scientific Advisory Board

Dr. Arepally is Professor of Medicine and Vice Chief of Research in the Division of Hematology at Duke University Medical Center. Her career has focused on immune thrombocytopenias, thrombotic disorders, and applications of therapeutic apheresis for immunologic disorders. Dr. Arepally’s long-standing research program investigates immunoregulatory mechanisms in HIT, research that led to the discovery of the role of complement activation in the immune pathogenesis of HIT. Dr. Arepally received her M.D. from Vanderbilt University, completed residency in Internal Medicine at Emory University where she was Chief Medical Resident and finished subspecialty training in Hematology/Oncology at the University of Pennsylvania.


Adam Cuker, M.D., M.S.

Adam Cuker, M.D., M.S.

Scientific Advisory Board

Dr. Cuker is Associate Professor of Medicine and of Pathology and Laboratory Medicine at the University of Pennsylvania. He also serves as Director of the Penn Comprehensive Hemophilia & Thrombosis Program, Assistant Director of the Penn Specialized Coagulation Laboratory, and Associate Director of the Penn-CHOP Blood Center for Patient Care and Discovery. He conducts NIH-funded patient-oriented research on heparin-induced thrombocytopenia, venous thromboembolism, and anticoagulation. Dr. Cuker received his M.D. from Yale University, completed an internship and residency in internal medicine at Brigham and Women’s Hospital and Harvard Medical School, and completed a fellowship in hematology/oncology at the Hospital of the University of Pennsylvania. He served as Chair of the 2018 American Society of Hematology Clinical Practice Guideline Panel on heparin-induced thrombocytopenia.


Michael Hanna, M.D

Michael Hanna, M.D

Scientific Advisory Board

Dr. Hanna is a cardiologist, electrophysiologist and clinical trialist with extensive experience in thrombosis, anticoagulation, heart failure, antiarrythmic drugs and medical devices. As the clinical lead on Bristol-Myers Squibb’s Eliquis program, he directed the phase 3 effort through multiple indications (60,000 patients) leading to approval of the drug by the FDA in 2012. Dr. Hanna received an M.D. from the University of Connecticut and completed his residency and postdoctoral work at Columbia. Following residency, Dr. Hanna was Director of the EP fellowship program and EP lab director at Presbyterian and Pennsylvania Hospitals.


Ted Holman PhD

Ted Holman PhD

Scientific Advisory Board

Dr. Holman is Professor of Chemistry and Biochemistry at the University of California, Santa Cruz and a key opinion leader in the field of lipoxygenase biochemistry. He has investigated the biochemistry of lipoxygenases and their mechanism of inhibition for the past 25 years. His work led to the issuance of 11 patents focused on lipoxygenase inhibitors, with 4 focusing on the inhibition of human 12-lipoxygenase. Importantly, he is co-inventor of Veralox’s clinical product candidate. Dr. Holman received his Ph.D. from University of Minnesota, Minneapolis and completed post-doctoral training at Harvard University and University of California, San Francisco.


Steven McKenzie, M.D., PhD

Steven McKenzie, M.D., PhD

Scientific Advisory Board

Dr. Steven McKenzie received his M.D. and PhD from Perelman School of Medicine at the University of Pennsylvania. He did clinical training and postdoctoral research training at the Children’s Hospital of Philadelphia and the University of Pennsylvania. Dr. McKenzie is Thomas D.M. Cardeza Professor of Medicine and Director of Hematology and the Cardeza Foundation for Hematologic Research at Sidney Kimmel Medical College of Thomas Jefferson University. He is a world-renowned physician-scientist and expert in platelet biology, with a focus on immune-mediated thrombocytopenia and thrombosis syndromes. He also is co-inventor of VLX-1005 and developer of the gold standard clinically relevant heparin-induced thrombocytopenia and thrombosis mouse model utilized by the research community.


Raghu Mirmira, M.D., PhD

Raghu Mirmira, M.D., PhD

Scientific Advisory Board

Dr. Mirmira is the Eli Lilly Professor and Director of the Diabetes Center at Indiana University School of Medicine. He is an expert in the biology of the pancreatic islet as it relates to the pathogeneses of type 1 and type 2 diabetes. Dr. Mirmira’s team showed that 12-lipoxygenase contributes to islet oxidative stress in the setting of diabetes, and that the deletion or inhibition of 12-lipoxygenase in islets of mice enhances insulin secretion and prevents hyperglycemia. He has published more than 130 scientific papers in prestigious journals and is an international thought leader in the field of diabetes. Dr. Mirmira received an MD/PhD from The University of Chicago and completed his residency in Internal Medicine with subspecialty training in Diabetes and Endocrinology at the University of California at San Francisco.


Jerry Nadler, M.D

Jerry Nadler, M.D

Scientific Advisory Board

Dr. Nadler Professor of Medicine and Pharmacology and Dean of New York Medical College. He has extensive experience in inflammation and beta cell biology and its impact in diabetes and atherosclerosis. Dr. Nadler’s work led to the identification of key lipid signaling pathways relevant to diabetes complications and Beta cell dysfunction including the role of the 12-lipoxygenase pathway. He is widely considered a key opinion leader in the pathogenesis of diabetes with more than 200 peer-reviewed publications in the field. Importantly, Dr. Nadler is a co-inventor of Veralox’s lead clinical product candidate. Dr. Nadler received his M.D. from the University of Miami and completed fellowship training in Endocrinology and Diabetes at the University of Southern California.


Anand Padmanabhan, M.D.,PhD

Anand Padmanabhan, M.D.,PhD

Scientific Advisory Board

Dr. Padmanabhan is Medical director in Transfusion Medicine at the Versiti Blood Research Institute and Associate Professor of Pathology at the Medical College of Wisconsin. His research is focused on defining the immunological mechanism by which HIT antibodies cause thrombocytopenia and thrombosis and are aimed at improving diagnosis and treatment of this serious complication of heparin therapy. Dr. Padmanabhan is on the forefront of new assay and biomarker development for early detection of HIT/T. He received his medical degree from Thanjavur Medical College and completed graduate studies in Molecular Biology, Cell Biology and Biochemistry at Brown University.